Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 801–900 of 1,008
Hatch, A. J., Sibley, A. B., Starr, M. D., Brady, J. C., Jiang, C., Jia, J., Bowers, D. L., Pang, H., Owzar, K., Niedzwiecki, D., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.806 · Cited by 24
Identification of potential therapeutic targets for colorectal cancer by bioinformatics analysis
Yan, M., Song, M., Bai, R., Cheng, S., & Yan, W. (2016) · Oncology Letters · doi:10.3892/ol.2016.5328 · Cited by 23
“Several biomarkers have been established for the detection of metastatic CRC, including KRAS and RAS mutations (8,9).”
Brijwani, N., Jain, M., Dhandapani, M., Zahed, F., Mukhopadhyay, P., Biswas, M., Khatri, D., Radhakrishna, V. D., Majumder, B., Radhakrishnan, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01566-x · Cited by 23
Battaglin, F., Schirripa, M., Buggin, F., Pietrantonio, F., Morano, F., Boscolo, G., Tonini, G., Lutrino, E. S., Lucchetti, J., Salvatore, L., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4001-x · Cited by 25
“Although FOLFOX plus panitumumab is a standard first-line therapy option for RAS wild-type untreated mCRC patients [14], data on the adoption of anti-EGFRs in elderly mCRC patients are scarce and mostly derived from retrospective or small prospective studies of molecularly unselected patients.”
Choi, I. S., Kato, S., Fanta, P. T., Leichman, L., Okamura, R., Raymond, V. M., Lanman, R. B., Lippman, S. M., & Kurzrock, R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0965 · Cited by 23
“Finally, BRAFmutation is a known poor prognostic feature (1, 8, 9).”
BackgroundFukata, K., Yuasa, N., Takeuchi, E., Miyake, H., Nagai, H., Yoshioka, Y., & Miyata, K. (2019) · Surgery Today · doi:10.1007/s00595-019-01889-4 · Cited by 25
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer
Morris, V. K., & Strickler, J. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-070119-120448 · Cited by 23
Tsuji, A., Nakamura, M., Watanabe, T., Manaka, D., Matsuoka, H., Kataoka, M., Takeuchi, M., Ichikawa, W., & Fujii, M. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00845-y · Cited by 25
Mutational and co-mutational landscape of early onset colorectal cancer
Alshenaifi, J. Y., Vetere, G., Maddalena, G., Yousef, M., White, M. G., Shen, J. P., Vilar, E., Parseghian, C. M., Dasari, A., Morris, V. K., et al. (2025) · Biomarkers · doi:10.1080/1354750x.2024.2447089 · Cited by 25
“…specific driver genes and pathways, including anti-eGFR for KRAS wild-type, BRaF inhibitors for BRAF -mutated tumors, and immune checkpoint inhibitors for Msi-h tumors (Douillard et al., 2013; Kopetz et al., 2024; Kothari et al., 2014; sveen et al., 2020; taku et al., 2022; Whitehead et al., 2024).”
Pereira, A. A. L., Rêgo, J. F. M., Munhoz, R. R., Hoff, P. M., Sasse, A. D., & Riechelmann, R. P. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1044022 · Cited by 23
Malik, H. M. A., Khan, A. Z., Berry, D. P., Cameron, I. C., Pope, I., Sherlock, D., Helmy, S., Byrne, B., Thompson, M., Pulfer, A., et al. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.01.032 · Cited by 23
Bruera, G., Cannita, K., Tessitore, A., Russo, A. D., Alesse, E., Ficorella, C., & Ricevuto, E. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.10.004 · Cited by 26
Novel therapeutic agents in the treatment of metastatic colorectal cancer
Pai, S. G., & Fuloria, J. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i1.99 · Cited by 25
Current Trends in Cancer Therapy
Sekhon, N., Kumbla, R. A., & Mita, M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803547-4.00001-x · Cited by 30
Future perspectives of circulating tumor DNA in colorectal cancer
Nadal, C., Winder, T. L., Gerger, A., & Tougeron, D. (2017) · Tumor Biology · doi:10.1177/1010428317705749 · Cited by 27
Lai, A. Z., Schrock, A. B., Erlich, R., Ross, J. S., Miller, V. A., Yakirevich, E., Ali, S. M., & Braiteh, F. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0376 · Cited by 26
Biomarker-driven and molecular targeted therapies for colorectal cancers
Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.003 · Cited by 27
“On the other hand, however, in several subgroup analyses of phase III trials, the presence of the BRAF V600E mutation failed to demonstrate a predictive value, thought to be because of the small number of BRAF-mutant patients and lack of statistical power [22,65].”
BackgroundChiu, J. W. Y., Krzyzanowska, M. K., Serra, S., Knox, J. J., Dhani, N. C., MacKay, H. J., Hedley, D. W., Moore, M. J., Liu, G., Burkes, R. L., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.010 · Cited by 25
Self-citationMao, W., Zhou, J. F., Zhang, H., Qiu, L., Tan, H., Hu, Y., & Shi, H. (2018) · Abdominal Radiology · doi:10.1007/s00261-018-1740-8 · Cited by 24
Shepshelovich, D., Townsend, A. R., Espin‐Garcia, O., Latifovic, L., O’Callaghan, C. J., Jonker, D. J., Tu, D., Chen, E. X., Morgen, E. K., Price, T. J., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1819 · Cited by 23
Annunziata, M. C., Stefano, A. D., Fabbrocini, G., Leo, S., Marchetti, P., Romano, M. C., & Romano, I. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00811-7 · Cited by 25
Toffoli, E. C., Sheikhi, A., Lameris, R., King, L. A., van Vliet, A. A., Walcheck, B. K., Verheul, H. M. W., Spanholtz, J., Tuynman, J. B., de Gruijl, T. D., et al. (2021) · Cancers · doi:10.3390/cancers13215446 · Cited by 23
Erve, I. V. ’., Wesdorp, N. J., Medina, J. E., Ferreira, L., Leal, A., Huiskens, J., Bolhuis, K., van Waesberghe, J. T. M., Swijnenburg, R., van den Broek, D. A., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00223 · Cited by 30
Brammeld, J. S., Petljak, M., Martincorena, I., Williams, S. P., García‐Alonso, L., Dalmases, A., Bellosillo, B., Robles‐Espinoza, C. D., Price, S., Barthorpe, S., et al. (2017) · Genome Research · doi:10.1101/gr.213546.116 · Cited by 23
The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms
Sievers, C. K., Kratz, J. D., Zurbriggen, L. D., LoConte, N. K., Lubner, S. J., Uboha, N., Mulkerin, D. L., Matkowskyj, K. A., & Deming, D. A. (2016) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0036-1584292 · Cited by 25
Allegra, C. J., Rumble, R. B., & Schilsky, R. L. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.007898 · Cited by 22
Mésange, P., Bouygues, A., Ferrand, N., Sabbah, M., Escargueil, A. E., Savina, A., Chibaudel, B., Tournigand, C., André, T., de Gramont, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3187 · Cited by 24
Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment
Ryu, H. S., Kim, H. J., Ji, W. B., Kim, B. C., Kim, J. H., Moon, S. K., Kang, S. I., Kwak, H. D., Kim, E. S., Kim, C. H., et al. (2024) · Annals of Coloproctology · doi:10.3393/ac.2024.00059.0008 · Cited by 23
“15C) [176].”
Phenotypic analysis of T cells infiltrating colon cancers: Correlations with oncogenetic status
Chirica, M., Bourhis, L. L., Lehmann‐Che, J., Chardiny, V., Bouhidel, F. A., Foulboeuf, L., Gornet, J. M., Lourenço, N., Dulphy, N., Toubert, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016698 · Cited by 23
“, BRAF mutations).(9,10) Some studies suggest that these differential outcomes are in part driven by the capacity of the tumor to induce a strong immune response.”
BackgroundBeyond KRAS Status and Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Perkins, G., Pilati, C., Blons, H., & Laurent-Puig, P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.66 · Cited by 22
Wen, F., Yang, Y., Zhang, P., Zhang, J., Zhou, J., Tang, R., Chen, H., Zheng, H., Fu, P., & Li, Q. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095398 · Cited by 22
Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance
Temraz, S. N., Mukherji, D., & Shamseddine, A. I. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.009 · Cited by 25
Takahashi, N., Iwasa, S., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.74 · Cited by 26
“…of prospective trials indicated that RAS mutation, which consists of KRAS (exon 2, 3 and 4) and NRAS (exon 2, 3 and 4) mutations, is a newly identified predictive biomarker for no clinical benefit of anti-EGFR antibody treatment in metastatic CRC (Douillard et al, 2013; Van Cutsem et al, 2015).”
BackgroundKim, S. T., Lee, S.-J., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., & Park, Y. S. (2017) · Journal of Cancer · doi:10.7150/jca.18286 · Cited by 24
“Along with KRAS and BRAF, other epigenetic abnormalities, oncogenic alterations such as PIK3CA, NRAS, and other protein kinases may alter the effect of cetuximab [31, 34-38].”
BackgroundBaraniskin, A., Laethem, J. V., Wyrwicz, L. S., Güller, U., Wasan, H. S., Matysiak‐Budnik, T., Gruenberger, T., Ducreux, M. P., Carneiro, F., Cutsem, E. V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.021 · Cited by 24
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 23
Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients
Hamzehzadeh, L., Khadangi, F., Karimiani, E. G., Pasdar, A., & Kerachian, M. A. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.05.001 · Cited by 24
Dankner, M. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00195 · Cited by 24
Ma, C., Huang, C., Chang, T., Tsai, H., Su, W., Yeh, Y., Chen, P.-J., & Wang, J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.12.003 · Cited by 22
Clinical target sequencing for precision medicine of breast cancer
Tsuchida, J., Rothman, J. D., McDonald, K.-A., Nagahashi, M., Takabe, K., & Wakai, T. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1373-5 · Cited by 24
Harada, K., Okamoto, W., Mimaki, S., Kawamoto, Y., Bando, H., Yamashita, R., Yuki, S., Yoshino, T., Komatsu, Y., Ohtsu, A., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5479-6 · Cited by 23
Ryan, É. J., Creavin, B., & Sheahan, K. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01369 · Cited by 25
“In contrast, RAS mutations are more common in right-sided tumors and these mutations are associated with resistance to EGFR inhibitors (110).”
BackgroundCurrent controversies in the management of metastatic colorectal cancer
Vera, R., Alonso, V., Gallego-Plazas, J., González‐Flores, E., Guillén‐Ponce, C., Pericay, C., Rivera, F., Safont, M. J., & Valladares‐Ayerbes, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2808-6 · Cited by 25
“04) were more favorable for the combination group [30].”
BackgroundResultInfluentialSelf-citationGarcía-García, C., Rivas, M. A., Ibrahim, Y. H., Calvo, M. T., Gris‐Oliver, A., Rodríguez, O., Grueso, J., Antón, P., Guzmán, M., Aura, C. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3091 · Cited by 26
“Activating mutations in both pathways confer resistance to EGFRtargeting therapies (5, 11-13), providing a rationale for dual MEK and PI3K-pathway”
Self-citationde Macêdo, M. P., de Melo, F. M., Ribeiro, J. S., de Mello, C. A. L., Begnami, M. D. F. D. S., Soares, F. A., Carraro, D. M., & da Cunha, I. W. (2015) · Oncoscience · doi:10.18632/oncoscience.118 · Cited by 23
“Thus, testing for KRAS and NRAS mutations is necessary before anti-EGFR therapies are initiated in CRC patients [12, 14, 15].”
BackgroundStein, A., Schwenke, C., Folprecht, G., & Arnold, D. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.12.005 · Cited by 23
Stahler, A., Heinemann, V., Ricard, I., von Einem, J. C., Giessen-Jung, C., Westphalen, C. B., Michl, M., Heinrich, K., Miller-Phillips, L., Jelas, I., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03290-y · Cited by 21
Atreya, C. E., Greene, C., McWhirter, R. M., Ikram, N. S., Allen, I. E., Van Loon, K., Venook, A. P., Yeh, B. M., & Behr, S. C. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0165 · Cited by 21
Stintzing, S., Klein‐Scory, S., von Weikersthal, L. F., Fuchs, M., Kaiser, F., Heinrich, K., Modest, D. P., Hofheinz, R., Decker, T. W., Gerger, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.01174 · Cited by 25
“Even more important, a detrimental effect was shown when EGFR antibodies were used in combination with oxaliplatin for treatment of RAS mutant ( RAS mut) mCRC. 5,6 Additionally, sidedness of the primary tumor plays an important role.”
Targeting metastatic colorectal cancer – present and emerging treatment options
Berlin, J. D., & Ciombor, K. K. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s47582 · Cited by 24
Liu, J., Xie, L., Cheng, L., Qian, X., Liu, B., Hu, J. Y., Ren, W., & Yang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s86966 · Cited by 23
“Similarly, the PFS and objective response rate for mCRC patients with wild-type KRAS have been remarkably improved, when panitumumab is applied in combination with chemotherapy.(18,19,21) However, not all mCRC patients carrying wild-type KRAS respond to anti-EGFR therapy.”
Kiesewetter, B., Raderer, M., Steger, G. G., Bartsch, R., Pirker, R., Zöchbauer‐Müller, S., Prager, G. W., Krainer, M., Preusser, M., Schmidinger, M., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000066 · Cited by 23
Yamamoto, I., Nosho, K., Kanno, S., Igarashi, H., Kurihara, H., Ishigami, K., Ishiguro, K., Mitsuhashi, K., Maruyama, R., Koide, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14863 · Cited by 25
“Regarding this resistance, a mutation in KRAS codon 61 or 146 has been actively studied as a possible additional predictive biomarker for anti-EGFR therapy [6, 7].”
Backgroundβ-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
Ganesh, S., Shui, X., Craig, K. P., Koser, M. L., Chopda, G. R., Cyr, W. A., Lai, C.-J., Dudek, H., Wang, W., Brown, B. D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0605 · Cited by 21
Parisi, A., Cortellini, A., Cannita, K., Venditti, O., Camarda, F., Calegari, M. A., Salvatore, L., Tortora, G., Rossini, D., Germani, M. M., et al. (2020) · Cancers · doi:10.3390/cancers12051259 · Cited by 22
Tailored Systemic Therapy for Colorectal Cancer Liver Metastases
Czauderna, C., Luley, K. B., von Bubnoff, N. C. C., & Marquardt, J. U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111780 · Cited by 23
“shown to be mainly effective in KRAS-wt patients [54,56].”
BackgroundCompanion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials
Heertum, R. V., Scarimbolo, R., Ford, R., Berdougo, E., & O'Neal, J. M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s87561 · Cited by 28
“For example, the presence of KRAS mutations in colorectal cancers expressing EGFR often leads to resistance to anti-EGFR therapy.(10) Lastly, companion diagnostic assays may require large amounts of tissue samples for the evaluation of multiple biomarkers.”
Orlandi, A., Salvatore, M. D., Bagalá, C., Basso, M., Strippoli, A., Plastino, F., Calegari, M. A., Cassano, A., Astone, A., & Barone, C. A. (2014) · Journal of Cancer · doi:10.7150/jca.10478 · Cited by 23
“8 months) was seen in extended RAS analysis of the PRIME study (9) This observation induced us to consider the possibility that KRAS mutational status might also select patients with different sensitivity to Oxa.”
BackgroundGenetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment
Peters, M. L. B., Tseng, J. F., & Miksad, R. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.006 · Cited by 25
MicroRNAs as Therapeutic Targets and Colorectal Cancer Therapeutics
Yamamoto, H., & Mori, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42059-2_13 · Cited by 21
Chen, G., Yang, Z., Eshleman, J. R., Netto, G. J., & Lin, M. (2016) · BioMed Research International · doi:10.1155/2016/9850690 · Cited by 24
“The Colon/Rectal Cancer Panel from National Cancer Comprehensive Network (NCCN) recently revised its guideline (Version 2.2016) for anti-EFGR therapy by recommending genotyping of tumor tissues in all patients with metastatic CRC for the extended RASmutations as well asBRAFmutations (http://www.nccn.org/professionals/…”
BackgroundInfluentialThe rise of genomic profiling in ovarian cancer
Previs, R. A., Sood, A. K., Mills, G. B., & Westin, S. N. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1259069 · Cited by 26
“For example, the presence of RAS mutations in colorectal cancer is associated with decreased overall survival with panitumumab and chemotherapy [58].”
BackgroundDNA methylation epigenotype and clinical features of NRAS‐mutation(+) colorectal cancer
Takane, K., Akagi, K., Fukuyo, M., Yagi, K., Takayama, T., & Kaneda, A. (2017) · Cancer Medicine · doi:10.1002/cam4.1061 · Cited by 21
“The PRIME trial showed a detrimental effect of adding panitumumab to firstline FOLFOX in patients with RAS mutations [45].”
BackgroundKetzer, S., Schimmel, K. J. M., Koopman, M., & Guchelaar, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0590-9 · Cited by 25
Bruera, G., Pepe, F., Malapelle, U., Pisapia, P., Mas, A. D., Giacomo, D. D., Calvisi, G., Troncone, G., & Ricevuto, E. (2018) · Oncotarget · doi:10.18632/oncotarget.25180 · Cited by 23
Recent advances in understanding colorectal cancer
Stintzing, S. (2018) · F1000Research · doi:10.12688/f1000research.14604.1 · Cited by 23
Stintzing, S., Ivanova, B., Ricard, I., Jung, A., Kirchner, T., Tannapfel, A., Juette, H., Hegewisch‐Becker, S., Arnold, D., & Reinacher‐Schick, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00474 · Cited by 24
“EGFR (epithelial growth factor receptor) antibodies are not efficient in RAS (rat sarcoma) mutant tumors (3) and may even have a detrimental effect on overall survival (OS) if used in combination with oxaliplatin (4, 5).”
BackgroundRepurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
Yang, M., Schell, M. J., Loboda, A. P., Nebozhyn, M., Li, J., Teer, J. K., Pledger, W. J., & Yeatman, T. J. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1383 · Cited by 23
Advances in radiological staging of colorectal cancer
Goiffon, R., O’Shea, A., & Harisinghani, M. G. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.06.005 · Cited by 24
Ros, J., Baraibar, I., Martini, G., Salvà, F., Gonzalez, N. S., Cuadra‐Urteaga, J. L., Dienstmann, R., Tabernero, J. M., & Élez, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00913-5 · Cited by 25
Self-citationAntibody-Based Immunotoxins for Colorectal Cancer Therapy
Sanz, L., Ibáñez-Pérez, R., Guerrero‐Ochoa, P., Lacadena, J., & Anel, A. (2021) · Biomedicines · doi:10.3390/biomedicines9111729 · Cited by 21
“However, these targeted therapies, which increase progression-free survival and overall survival, are effective only in the absence of downstream activating mutations in EGFR signalling, such as KRAS and NRAS [118].”
BackgroundO’Neil, B. H., & Venook, A. P. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8495 · Cited by 22
Notch receptor/ligand diversity: contribution to colorectal cancer stem cell heterogeneity
Brisset, M., Mehlen, P., Meurette, O., & Hollande, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1231416 · Cited by 20
Ma, B. B. Y., Mo, F. K. F., TONG, J. H. M., Wong, C. Y., Wong, S. C. C., Ho, W. M., Wu, Ç., Lam, P. W., Chan, K.-F., Chan, T. S. K., et al. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12342 · Cited by 21
Treatment Individualization in Colorectal Cancer
van Geel, R. M. J. M., Beijnen, J. H., Bernards, R., & Schellens, J. H. M. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0288-z · Cited by 22
“As RAS mutations predict resistance to anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab, patients with RAS mutant disease should be excluded from treatment with these drugs [7 – 11].”
Capalbo, C., Marchetti, P., Coppa, A., Calogero, A., Anastasi, E., Buffone, A., Belardinilli, F., Gulino, M., Frati, P., Catalano, C., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28878 · Cited by 21
“While the use of positive predictive biomarkers for biological therapy would be desirable in order to identify specific subsets of responsive patients, to date the only validated negative predictive biomarker for mCRC is the mutational status of all members of the RAS gene family, which identifies mCRC patients not el…”
BackgroundTranslational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts
Krüger, S., Haas, M., Ormanns, S., Baechmann, S., Siveke, J. T., Kirchner, T., Heinemann, V., & Boeck, S. H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10769 · Cited by 22
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
Mardjuadi, F. I., Carrasco, J., Coche, J.-C., Sempoux, C. L., Jouret‐Mourin, A., Scalliet, P. G. M., Goeminne, J., Daisne, J., Delaunoit, T., Vuylsteke, P., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0342-9 · Cited by 21
Self-citationOttaiano, A., Capozzi, M., Tafuto, S., Stefano, A. D., Divitiis, C. D., Romano, C., Avallone, A., & Nasti, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00766 · Cited by 20
“Anti-EGFR (Epidermal Growth Factor Receptors) drugs (cetuximab and panitumumab) are monoclonal antibodies administered both as single agents or with chemotherapy in first, second or third-line setting of mCRC; they bind to EGFR preventing the activation of downstream signal proteins involved in promoting proliferation…”
BackgroundMethodNixon, A. B., Sibley, A. B., Liu, Y., Hatch, A. J., Jiang, C., Mulkey, F., Starr, M. D., Brady, J. C., Niedzwiecki, D., Venook, A. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2389 · Cited by 23
Nero, C., Duranti, S., Giacomini, F., Minucci, A., Giacò, L., Piermattei, A., Genuardi, M., Pasciuto, T., Urbani, A., Daniele, G., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101746 · Cited by 22
Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review)
Wang, C., Zhang, H., Liu, Y., Wang, Y., Hu, H., & Wang, G. (2023) · Oncology Letters · doi:10.3892/ol.2023.13816 · Cited by 25
Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study
Turhal, N. S., Savaş, B., Coşkun, Ö., Baş, E., Karabulut, B., Nart, D., Korkmaz, T., Yavuzer, D., DEMIR, G., Doğusoy, G., et al. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.633 · Cited by 20
“The majority of K‑Ras genes are located on exon 2 and mutations in codons 12, 13, 146 and 154 are the most frequent; >80% of mutations occur in codons 12 and 13 (25-27).”
Yang, C., & Fu, Z. (2014) · Biomedical Reports · doi:10.3892/br.2014.249 · Cited by 20
“Oxaliplatin acts synergistically with other anticancer drugs, such as fluorouracil, topoisomerase inhibitors and microtubule inhibitors (7,8).”
The Cancer Genomics Resource List 2014
Zutter, M. M., Bloom, K. J., Cheng, L., Hagemann, I. S., Kaufman, J. H., Krasinskas, A. M., Lazar, A. J., Leonard, D. G. B., Lindeman, N. I., Moyer, A. M., et al. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0330-cp · Cited by 20
BRAF in Metastatic Colorectal Cancer: The Future Starts Now
Orlandi, A., Calegari, M. A., Inno, A., Berenato, R., Caporale, M., Niger, M., Bossi, I. E., Bartolomeo, M. D., de Braud, F., & Pietrantonio, F. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.140 · Cited by 20
Venook, A. P., Arcila, M. E., Benson, A. B., Berry, D. A., Camidge, D. R., Carlson, R. W., Choueiri, T. K., Guild, V., Kalemkerian, G. P., Kurzrock, R., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0161 · Cited by 20
Liddell, C., Droy-Dupré, L., Métairie, S., Airaud, F., Volteau, C., Bezieau, S., LABOISSE, C. L., & Mosnier, J. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.18 · Cited by 21
Moorcraft, S.-Y., de Castro, D. G., Cunningham, D., Jones, T., Walker, B. A., Peckitt, C., Yuan, L., Frampton, M., Begum, R., Eltahir, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx631 · Cited by 21
Self-citationMessaritakis, I., Sfakianaki, M., Papadaki, C., Koulouridi, A., Vardakis, N., Koinis, F., Hatzidaki, D., Georgoulia, N., Kladi, A., Kotsakis, A. P., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3666-9 · Cited by 20
Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients
Ottaiano, A., Scala, S., Normanno, N., Botti, G., Tatangelo, F., Mauro, A. D., Capozzi, M., Facchini, S., Tafuto, S., & Nasti, G. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000828 · Cited by 21
Belardinilli, F., Capalbo, C., Malapelle, U., Pisapia, P., Raimondo, D., Milanetti, E., Mahdavian, Y., Liccardi, C., Paci, P., Sibilio, P., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00560 · Cited by 22
“In example, the use of anti-EGFR therapy is essentially dictated by the RAS (KRAS+NRAS) wild type status, in the clinical routine (17, 18), which however is largely insufficient for the positive selection of responsive patients (19, 20).”
BackgroundCirculating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer
Osumi, H., Shinozaki, E., & Yamaguchi, K. (2020) · Cancers · doi:10.3390/cancers12061566 · Cited by 21
Chang, X., Shang, F., Jiang, H., Chen, C., Zhao, Z., Deng, S., Fan, J., Dong, X., Yang, M., Li, Y., et al. (2021) · Current Medical Science · doi:10.1007/s11596-021-2326-1 · Cited by 22
Kumar, S. S., Tomita, Y., Wrin, J., Bruhn, M. A., Swalling, A., Mohammed, M., Price, T. J., & Hardingham, J. E. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1596-8 · Cited by 22
Saad, A. M., & Abdel-Rahman, O. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1642324 · Cited by 20
Zhou, T., & Ji, Y. (2021) · Statistics in Medicine · doi:10.1002/sim.9191 · Cited by 27
Granata, V., Fusco, R., Setola, S. V., Galdiero, R., Maggialetti, N., Patrone, R., Ottaiano, A., Nasti, G., Silvestro, L., Cassata, A., et al. (2023) · Infectious Agents and Cancer · doi:10.1186/s13027-023-00495-x · Cited by 19
Yu, Q., Jiang, H., Su, X., Jiang, Z., Liang, X., Zhang, C., Shang, W., Zhang, Y., Chen, H., Yang, Z., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.03.002 · Cited by 23
Stahler, A., Kind, A. J., Sers, C., Mamlouk, S., Müller, L., Karthaus, M., Fruehauf, S., Graeven, U., von Weikersthal, L. F., Sommerhäuser, G., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3023 · Cited by 21
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.